Watchlist Price Alert

MaxCyte Inc. (MXCT)

NASDAQ: MXCT · Real-Time Price · USD

2.35

-0.08 (-3.29%)

At close: May 09, 2025, 3:59 PM

2.35

0.00%

After-hours: May 09, 2025, 04:05 PM EDT

-3.29% (1D)

Bid	2.31
Market Cap	250.37M
Revenue (ttm)	38.63M
Net Income (ttm)	-41.05M
EPS (ttm)	-0.39
PE Ratio (ttm)	-6.04
Forward PE	-9.17
Analyst	Buy

Ask	3
Volume	1,747,830
Avg. Volume (20D)	661,108
Open	2.43
Previous Close	2.43
Day's Range	2.31 - 2.44
52-Week Range	2.21 - 5.26
Beta	1.13

About MXCT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MXCT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MXCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

MaxCyte has released their quartely earnings on May 7, 2025:

Revenue of $10.39M exceeds estimates by $1.34M, with -8.39% YoY decline.

EPS of -0.1 misses estimates by 0.00, with -11.11% YoY decline.

Why Price Moved

3 months ago

+11.59%

MaxCyte shares are trading higher after the compan... Unlock content with Pro Subscription

5 months ago

+15.83%

MaxCyte shares are trading higher after the company raised its FY24 core revenue guidance and announced layoffs to save $5.8 million per year.

News

3 days ago · zacks.com

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.

1 month ago · zacks.com

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)

MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e...

1 month ago · zacks.com

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c...

1 month ago · zacks.com

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · seekingalpha.com

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by th...

2 months ago · seekingalpha.com

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Start Time: 16:30 January 1, 0000 5:12 PM ET MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2024 Earnings Conference Call March 11, 2025, 16:30 PM ET Company Participants Maher Masoud - President and CEO Doug Swirsk...